Inspira Technologies Oxy B.H.N. Ltd. Warrant - IINNW STOCK NEWS

Inspira Technologies, a company aiming to revolutionize acute respiratory care, has released its latest investor deck. The deck highlights their vision, achievements, and projected targets for the second half of 2023. It showcases their cutting-edge extracorporeal blood circulation medical devices, including the INSPIRA™ ART500, which is designed to provide respiratory support without the need for mechanical ventilators. The deck also emphasizes the market potential of the company, with an estimated $20 billion total addressable market for their technologies.

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN)(NASDAQ:IINNW) is set to present at the 2023 Planet MicroCap Showcase in Las Vegas on April 26, 2023, at 14:30 CST. Joe Hayon, President and Co-Founder, will lead the presentation. Interested parties can access the live presentation via the provided webcast link. Registration for the event is necessary, which can be done here. Additionally, one-on-one virtual meetings can be scheduled with Joe throughout May by using this link. Inspira Technologies focuses on innovative respiratory treatments, particularly its Augmented Respiration Technology, aimed at improving patient outcomes while minimizing the use of invasive mechanical ventilation.

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) reported its financial results for the year ended December 31, 2022. The company has $13.9 million in cash, a decrease from $23.7 million in 2021, with shareholders' equity falling to $12.8 million from $20.3 million. R&D expenses increased to $8 million from $3.9 million in the previous year. The net loss showed improvement at $10.3 million compared to $17 million in 2021. The company plans to submit its ALICE device for FDA approval in H2 2023 and is conducting clinical studies for its HYLA blood sensor. Inspira continues to advance its INSPIRA ART system aimed at non-invasive respiratory treatment.

Inspira Technologies has announced the first-in-human use of its HYLA Blood sensor during open-heart surgery at Sheba Medical Center in Israel. This non-invasive sensor utilizes machine learning to measure key blood parameters in real-time, aiming to enhance patient care during procedures like VV-ECMO and VA-ECMO. The ongoing HYLA clinical study compares the sensor's performance against traditional blood gas analyzers. The company's advanced Augmented Respiration Technology (INSPIRA ART) seeks to improve oxygen saturation levels without invasive ventilation methods. Regulatory approval is still pending for these technologies.